The Global Resource For Connecting Buyers and Sellers

BerGenBio to Present Overview of Phase II Clinical Trial Portfolio Combining Bemcentinib With KEYTRUDA at 3rd Annual Immuno-Oncology Summit Europe

BERGEN, Norway, 22 March 2018 /PRNewswire/ –BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors as a potential cornerstone of combination cancer therapy, announces that the Company will be presenting an overview of the…